SEC and Justice Department lawyers sided with investors suing government contractor Leidos Inc. over its failure to disclose in a corporate annual report its involvement in a fraudulent billing scheme.
An omission from the management narrative known as the MD&A can form the basis of a private federal securities fraud claim, the government lawyers told the U.S. Supreme Court in a Sept. 7 friend of the court brief ( Leidos, Inc. v. Ind. Pub. Ret. Sys., U.S., No. 16-581, amicus brief filed 9/7/17 ).
The MD&A—standing for Management’s Discussion and Analysis—requires companies to disclose known trends and uncertainties that could affect their business.
Leidos argued that for an MD&A omission to be actionable, the shareholders have to show that the information was needed to make another statement by the company not misleading, which wasn’t the case here.
The SEC and DOJ disagreed. This case “involves a half-truth rather than a pure omission,” the government said. The MD&A in question “appeared to be complete and thus conveyed to a reasonable investor that it disclosed all of the information [1934 Securities Exchange Act] Item 303 required,” the lawyers said.
If Leidos’ approach were accepted, “it would create a significant loophole in Section 10(b) by transforming a disclosure obligation designed to protect investors even when there is no fraud into a shelter or sanctuary for those who defraud investors,” the SEC and DOJ said. Section 10(b) is the securities laws general antifraud proscription.
According to investors, Leidos artificially inflated its stock price by filing shareholder reports that disclosed some known trends and uncertainties but didn’t disclose that it had been implicated in a fraudulent overbilling scheme in the “City-Time” project with the City of New York. After full disclosure, the company’s stock price fell from $17.21 to $12.97 per share.
The district court dismissed the suit, saying investors didn’t adequately plead that Leidos’ MD&A violated Item 303 or that the company acted with scienter—culpable intent. The U.S. Court of Appeals for the Second Circuit reversed. It said Item 303 imposes an “affirmative duty to disclose” that can serve as the basis for a securities fraud claim under Section 10(b).
The case is scheduled for oral argument Nov. 6.
To contact the reporter on this story: Antoinette Gartrell in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Phyllis Diamond at email@example.com
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)